Physician profile
Abraham Glasman
NPI 1780680991
$1,945.62
in general payments reported to CMS, 2019-2025
32 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $308 · 2021: $972 · 2022: $217 · 2023: $53.20 · 2024: $20.00 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.58 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $373.94 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $264.28 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $186.23 | 2020-2021 | |
| Horizon Therapeutics Plc | $161.93 | 2021 | |
| Avanir Pharmaceuticals, INC. | $155.43 | 2021 | |
| Allergan, INC. | $151.75 | 2020-2022 | |
| Ucb, INC. | $125.00 | 2025 | Rystiggo |
| Mdd US Operations, LLC | $45.82 | 2019 | |
| Csl Behring | $40.68 | 2021-2024 | Kcentra |
| Catalyst Pharmaceuticals, INC. | $34.49 | 2020-2021 | |
| Boston Scientific Corporation | $27.83 | 2019 | |
| Sunovion Pharmaceuticals INC. | $26.07 | 2021 | |
| Acadia Pharmaceuticals INC | $25.99 | 2019 | |
| Pfizer INC. | $23.65 | 2021 | |
| Medtronic, INC. | $22.32 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $22.23 | 2021 | |
| Amgen INC. | $21.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.82 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.75 | 2020 | |
| Genzyme Corporation | $19.10 | 2019 | |
| Zyla Life Sciences, INC. | $18.75 | 2019 | |
| Scilex Pharmaceuticals INC. | $18.03 | 2019 | |
| Eisai INC. | $17.38 | 2025 | |
| Upsher-Smith Laboratories LLC | $17.30 | 2021 | |
| Abbott Laboratories | $17.19 | 2019 | |
| Biogen, INC. | $16.83 | 2021 | |
| Celgene Corporation | $13.46 | 2022 | |
| Almatica Pharma LLC | $12.52 | 2021 | |
| Octapharma USA, INC. | $12.50 | 2022 | |
| Greenwich Biosciences, INC. | $11.75 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Glasman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.